LU Bioscience invests in start-up company with focus on stroke
LU Bioscience AB announced the establishment and investment in a novel company, Auril AB, developing a therapeutic agent for induction of temperature reduction in cardiac arrest and stroke patients.
The project that is in focus for the investment has been developed by Professor Tadeusz Wieloch and Carin Sjölund at Lund University. A mutually owned company has been established by LUBio and the inventors. The purpose for the new company is to further develop the project into a drug to induce hypothermia.
"Temperature reduction in patients suffering from ischemia has proven efficient in reducing brain damage. Cooling of patients is routinely used today in patients suffering from cardiac arrest, but there is presently no approved way of cooling stroke patients." says Tadeusz Wieloch, Professor in Neurobiology.
"This is the second investment in inventions from Lund University in a very short time. We are happy to be able to add a collaboration with Prof Wieloch, who is one of the leaders in stroke research, to our growing portfolio of companies", says Thomas Andersson, CEO of LU Bio.
Other news from the department business & finance
